# 2025-16265: FDA Clocks IQIRVO Review Time for Patent Perks

2025-16265, Determination of Regulatory Review Period for Purposes of Patent Extension; IQIRVO, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-26 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16265
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16265
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; IQIRVO
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41569
- Published: 2025-08-26
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Clocks IQIRVO Review Time for Patent Perks

## Summary

The FDA has officially set the review period for IQIRVO, a human drug product, so its patent can be extended. This helps the company behind IQIRVO get extra time to protect their invention after going through the FDA’s approval process. If you’re involved in drug patents or development, this means important deadlines and opportunities to keep an invention exclusive just got clearer.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IQIRVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

## Effects PRIA read

- FDA Sets Patent-Extension Review Period: benefit, medium. The FDA has determined the regulatory review period for the drug IQIRVO so the patent holder can apply for a patent extension. If you work in drug development or hold the IQIRVO patent, this lets the company seek extra time to keep the invention exclusive after FDA review.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16265 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/26/2025-16265/determination-of-regulatory-review-period-for-purposes-of-patent-extension-iqirvo)
- [2025-16265 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16265.pdf)

## Related
- [Previous: 2025-16264, Notice of OFAC Sanctions Actions](https://policyrisk.com/federal-register/2025-16264)
- [Next: 2025-16266, Determination of Regulatory Review Period for Purposes of Patent Extension; LUM…](https://policyrisk.com/federal-register/2025-16266)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16265 (as of 2026-06-08).
